Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 28 September 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Identifying patients at lower risk for esophageal adenocarcinoma

Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma, reports this month's issue of Gastroenterology.

News image

Recent population-based studies have shown a low risk of esophageal adenocarcinoma in patients with nondysplastic Barrett’s esophagus.

Dr Srinivas Gaddam from Missouri, USA evaluated whether persistence of nondysplastic Barrett’s esophagus over multiple consecutive surveillance endoscopic examinations could be used in risk stratification of patients with Barrett’s esophagus.

The team performed a multicenter outcomes study of a large cohort of patients with Barrett’s esophagus.

Based on the number of consecutive surveillance endoscopies showing nondysplastic Barrett’s esophagus, the team identified 5 groups of patients.

Patients in group 1 were found to have nondysplastic Barrett’s esophagus at their first esophagogastroduodenoscopy.

The median follow-up period was 5 years
Gastroenterology

Patients in group 2 were found to have nondysplastic Barrett’s esophagus on their first 2 consecutive esophagogastroduodenoscopies.

Similarly, patients in groups 3, 4, and 5 were found to have nondysplastic Barrett’s esophagus on 3, 4, and 5 consecutive surveillances for esophageal adenocarcinoma.

A logistic regression model was built to determine whether persistence of nondysplastic Barrett’s esophagus independently protected against development of cancer.

Of a total of 3515 patients with Barrett’s esophagus, 1401 patients met the inclusion criteria.

The median follow-up period was 5 years.

The team noted that the annual risk of esophageal adenocarcinoma in groups 1 to 5 was 0.32%, 0.27%, 0.16%, 0.2%, and 0.11%, respectively.

After adjusting for age, sex, and length of Barrett’s esophagus, persistence of nondysplastic Barrett’s esophagus, based on multiple surveillance endoscopies, was associated with a gradually lower likelihood of progression to esophageal adenocarcinoma.

Dr Gaddam's team concludes, "Persistence of nondysplastic Barrett’s esophagus over several endoscopic examinations identifies patients who are at low risk for development of esophageal adenocarcinoma."

"These findings support lengthening surveillance intervals or discontinuing surveillance of patients with persistent nondysplastic Barrett’s esophagus."

Gastroenterol 2013: 145(3) 548-553
09 September 2013

Go to top of page Email this page Email this page to a colleague

 28 September 2016 
Global trends in pancreatic cancer mortality
 28 September 2016 
Hep C virus RNA in liver explants
 28 September 2016 
Heterogeneity in endoscopic treatment of Crohn’s
 27 September 2016 
Non-invasive tests of NAFLD
 27 September 2016 
Fecal microbiota transplantation for C.diff in IBD
 27 September 2016 
Fast-track colorectal surgery influences outcomes
 26 September 2016 
Preventing cirrhosis in Hep C with fibrosis
 26 September 2016 
Body image after abdominoperineal excision for rectal cancer
 26 September 2016 
Gastric cancer risk in intestinal metaplasia of the stomach
 23 September 2016 
Sleep quality in nonalcoholic cirrhotic patients
 23 September 2016 
Exercise for NAFLD
 23 September 2016 
BMI history and fatty liver
 22 September 2016 
Predicting small-bowel Crohn’s disease
 22 September 2016 
Colectomy outcomes for ulcerative colitis
 22 September 2016 
Technology vs intervention for weight loss
 21 September 2016 
Employment status and IBD
 21 September 2016 
Cardiopulmonary exercise testing in liver transplant candidates
 21 September 2016 
Patients vs providers on nutrition in IBD
 20 September 2016 
Improving healthcare systems for viral Hepatitis
 20 September 2016 
GI benefits of COX-2 selective inhibitors
 20 September 2016 
Predicting relapse in Crohn's
 19 September 2016 
Prevalence of esophageal cancer in Barrett's
 19 September 2016 
Fecal microbiota transplantation and CDI in IBD
 19 September 2016 
Antibiotic resistance in Helicobacter pylori
 16 September 2016 
Low-residue diet before colonoscopy and bowel cleansing
 16 September 2016 
Genome-wide association in gastric cancer
 16 September 2016 
H. pylori in children with asthma
 15 September 2016 
Improving survival in cholangitis-associated septic shock
 15 September 2016 
Colorectal cancer survival and hospital volumes
 15 September 2016 
Primary sclerosing cholangitis and IBD
 14 September 2016 
Intestinal malabsorption and olmesartan
 14 September 2016 
Infection reduction strategy after colorectal resection
 14 September 2016 
Predicting long-term infliximab use in Crohn's
 13 September 2016 
Predicting survival in refractory celiac disease
 13 September 2016 
Cancer risk stratification in Barrett’s
 13 September 2016 
Screening vs non-screening colonoscopy
 12 September 2016 
Screening in familial colorectal cancer
 12 September 2016 
Metformin improves survival in pancreatic ductal cancer
 12 September 2016 
Consent guidelines for GI endoscopy procedures
 09 September 2016 
Development of IBS
 09 September 2016 
Safe and effective treatment for NASH
 09 September 2016 
Scale for stool measurement in diarrhea-IBS
 08 September 2016 
Prognostic factors for infliximab in Crohn's
 08 September 2016 
Chronic Hep B vs chronic Hep C and mortality
 08 September 2016 
Hematological malignancies in IBD
 07 September 2016 
IBD relapse during pregnancy
 07 September 2016 
New treatments for ulcerative colitis
 07 September 2016 
Alternative to nucleic acid testing in HCV
 06 September 2016 
EHealth technologies in IBD
 06 September 2016 
Endoscopy clinic no-shows
 06 September 2016 
Risk of infection after elective colorectal surgery
 05 September 2016 
Esophageal impedance monitoring
 05 September 2016 
Biomarker for IBD and GI cancer
 05 September 2016 
Family history and IBD clinical course
 02 September 2016 
Dietary carbohydrate intake, insulin resistance and GERD 
 02 September 2016 
Postpolypectomy bleeding in the colorectum
 02 September 2016 
Postop recurrence of Crohn's
 01 September 2016 
Prognostic test for liver transplants
 01 September 2016 
Recovery after colorectal surgery in elderly patients
 01 September 2016 
Obesity and post-ERCP pancreatitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us